KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Twist Bioscience (TWST) EPS (Weighted Average and Diluted) (2020 - 2026)

Twist Bioscience has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$0.71 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 7.58% to -$0.71 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.33 through Mar 2026, up 59.08% year-over-year, with the annual reading at -$1.3 for FY2025, 63.89% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.71 for Q1 2026 at Twist Bioscience, down from -$0.5 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.33 in Q2 2025 and troughed at -$1.47 in Q2 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.75 (2023), against an average of -$0.75.
  • Year-over-year, EPS (Weighted Average and Diluted) plummeted 45.54% in 2024 and then soared 122.45% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.74 in 2022, then fell by 1.35% to -$0.75 in 2023, then rose by 29.33% to -$0.53 in 2024, then rose by 5.66% to -$0.5 in 2025, then tumbled by 42.0% to -$0.71 in 2026.
  • Per Business Quant, the three most recent readings for TWST's EPS (Weighted Average and Diluted) are -$0.71 (Q1 2026), -$0.5 (Q4 2025), and -$0.45 (Q3 2025).